Definium Therapeutics
DFTX
155 hedge funds and large institutions have $130M invested in Definium Therapeutics in 2021 Q2 according to their latest regulatory filings, with 155 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
44% more call options, than puts
Call options by funds: $9.65M | Put options by funds: $6.68M
0.74% more ownership
Funds ownership: 0% → 0.74% (+0.74%)
Top Buyers
| 1 |
BlackRock
New York
|
+$54.9M |
| 2 |
State Street
Boston,
Massachusetts
|
+$15.7M |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$9.49M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$5.84M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$4.33M |
Top Sellers
DFTX Hedge Fund Activity: Q2 2021 in Review
155 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Definium Therapeutics (DFTX) for Q2 2021, worth a combined $130M.
Buyers outnumbered sellers: 155 funds opened new DFTX positions and 0 closed out — a net gain of 155 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was BlackRock, opening a new position worth an estimated $54.9M.
- 155 institutional investors held Definium Therapeutics (DFTX) as of Q2 2021, up from 0 in Q1 2021.
- Funds reported $130M of Definium Therapeutics stock for Q2 2021.
- 155 funds opened new Definium Therapeutics positions in Q2 2021 and 0 closed out, a net change of +155 holders.
- The largest Definium Therapeutics buyer in Q2 2021 was BlackRock, an estimated $54.9M added.
Based on aggregated 13F filings for Q2 2021.